Efforts to eliminate hepatitis gain momentum

Efforts to eliminate hepatitis gain momentum PharmacoEconomics & Outcomes News 784, p2 - 12 Aug 2017 Efforts to eliminate hepatitis gain momentum New WHO data reveal that efforts to eliminate hepatitis are gaining momentum in 28 countries which account for 70% of the global hepatitis burden. The data were published on World Hepatitis Day and shows that nearly all of the 28 countries have set up high-level national hepatitis elimination committees, with over half having dedicated funding allocated for hepatitis response. Over 86% of countries reviewed have established national hepatitis elimination targets, whilst over 70% have started the development of national plans to allow access to effective services for the prevention, diagnosis, treatment and care of hepatitis. WHO Director-General, Dr Tedros Adhanom Ghebreyesus, commented that "it is encouraging to see countries turning commitment into action to tackle hepatitis". However, WHO believes that countries need to accelerate their efforts and provide further investment in order for hepatitis elimination to become a reality. With the aim of increasing access to therapy, WHO has added the first generic version of a direct acting antiviral, sofosbuvir, to its list of pre-qualified hepatitis C medicines. A 3-month treatment course of this generic will cost $US260–$280 and can now be procured by the United Nations and financing agencies such as UNITAID. Additionally, WHO is promoting the prevention of hepatitis through injection safety via a new campaign titled "Get the Point – Make smart injection choices". The global hepatitis agenda will be further advanced during the World Hepatitis Summit to be held in Sao Paulo, Brazil, from 1–3 November 2017, which is themed "Implementing the Global health sector strategy on viral hepatitis: towards the elimination of hepatitis as a public health threat". WHO. Eliminate hepatitis: WHO. Internet Document : 27 Jul 2017. Available from: URL: http://www.who.int/mediacentre/news/releases/2017/eliminate- hepatitis/en/ 803262347 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Efforts to eliminate hepatitis gain momentum

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/efforts-to-eliminate-hepatitis-gain-momentum-HSok2kVFTB
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4213-3
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p2 - 12 Aug 2017 Efforts to eliminate hepatitis gain momentum New WHO data reveal that efforts to eliminate hepatitis are gaining momentum in 28 countries which account for 70% of the global hepatitis burden. The data were published on World Hepatitis Day and shows that nearly all of the 28 countries have set up high-level national hepatitis elimination committees, with over half having dedicated funding allocated for hepatitis response. Over 86% of countries reviewed have established national hepatitis elimination targets, whilst over 70% have started the development of national plans to allow access to effective services for the prevention, diagnosis, treatment and care of hepatitis. WHO Director-General, Dr Tedros Adhanom Ghebreyesus, commented that "it is encouraging to see countries turning commitment into action to tackle hepatitis". However, WHO believes that countries need to accelerate their efforts and provide further investment in order for hepatitis elimination to become a reality. With the aim of increasing access to therapy, WHO has added the first generic version of a direct acting antiviral, sofosbuvir, to its list of pre-qualified hepatitis C medicines. A 3-month treatment course of this generic will cost $US260–$280 and can now be procured by the United Nations and financing agencies such as UNITAID. Additionally, WHO is promoting the prevention of hepatitis through injection safety via a new campaign titled "Get the Point – Make smart injection choices". The global hepatitis agenda will be further advanced during the World Hepatitis Summit to be held in Sao Paulo, Brazil, from 1–3 November 2017, which is themed "Implementing the Global health sector strategy on viral hepatitis: towards the elimination of hepatitis as a public health threat". WHO. Eliminate hepatitis: WHO. Internet Document : 27 Jul 2017. Available from: URL: http://www.who.int/mediacentre/news/releases/2017/eliminate- hepatitis/en/ 803262347 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off